EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

CompletedOBSERVATIONAL

Enrollment

1,180

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC

Trial Locations (1)

Bayer Flatiron Xofigo Registry database, Whippany